Advertisement

Topics

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

2014-08-27 03:56:28 | BioPortfolio

Summary

Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically.

Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.

Description

Heat-shock proteins (HSP) are present within normal and cancerous cells. They are among the most ancient molecules in evolution, and are known as protein chaperones because of their abilities to bind polypeptide chains to assist in protein folding, transport or turnover. Works pioneered by Srivastava's group (Srivastava et al. 1998) have shown that HSPs can associate non-covalently with antigenic peptides. Injection of HSP-peptide complexes isolated from tumor cells can induce tumor protection against both pre-established tumors and subsequent tumor challenge by eliciting specific cytotoxic T lymphocyte (CTL) response against a variety of tumors in animals such as sarcoma, lymphoma, melanoma, hepatoma, prostate cancer and lung cancer (Tamura et al).

A previous trial on the role of HSP70 in breast cancer treatment was targeted specifically against patients who had widespread metastasis and who had failed all conventional therapy including intensive multi-agent chemotherapy with DTEC (decadron, taxol, etoposide and cyclophosphamide).

This pilot study has shown that, (1) HSP70 can be purified successfully from breast cancer cells. (2) The yield of HSP70 is extremely variable and cannot be predicted accurately based on the size of the tumor because of significant heterogeneity of histology and patient's prior history of chemotherapy. (3) HSP70 vaccination is safe and well tolerated.

Hypothesis and current protocol

The biggest challenge of cancer management is to control metastasis. It is perhaps more obvious in breast cancer than in any other tumor. Breast cancer patients rarely die of primary cancer. The tendency of a deadly relapse in distal sites, after years of "remission" is the common cause of mortality. Even with newly diagnosed patients who present with stage IV breast cancer, complete response can be achieved in more than 40% of patients with the current multi-modality approach. However, patients with stage IV breast cancer are "never" cured because of the risk of late relapses.

There are several reasons for the unsatisfactory results of immunotherapy in advanced and widespread cancers. First, the tumor burden is too overwhelming. Host defenses are simply over powered. Second, patients at this stage usually have significant co-morbidities, which prevent optimal immune responses. Third, advanced cancer patients often have a compromised functional state of the immune system either quantitatively or qualitatively due to prior cytotoxic therapy, radiation therapy, or as a result of active secretion of immunosuppressive agents by the tumor cells such as TGF-beta. Finally, there is simply not enough time to mount an effective adaptive immune response in these patients.

Therefore, we hypothesize that immunotherapy with HSP70 is more effective as "consolidation" therapy for high-risk patients who are rendered to have only minimal residue disease. To test this hypothesis, tumors from patients with high-risk breast cancer will be resected for HSP70 purification. This will be followed by conventional therapy such as hormonal therapy, chemotherapy, radiation therapy, or combined modality treatment. A total of 15 patients who are either in complete remission or in stable partial remission after standard therapy, will be enrolled to test the hypothesis that HSP70 vaccine will lead to improved tumor-specific T cell response in over 40% of patients. As a secondary endpoint, it will be determined whether the immunological responses can be correlated with disease-free survival or progression-free survival.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Neoplasms

Intervention

Heat Shock Protein 70-peptide complexes (HSP70)

Location

University of Connecticut Health Center
Farmington
Connecticut
United States
06030

Status

Terminated

Source

University of Connecticut Health Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:56:28-0400

Clinical Trials [3667 Associated Clinical Trials listed on BioPortfolio]

Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

Description: The trial is designed to determine the response of the immune system of patients with CML to a vaccine made from their own tumor. Researchers believe that this particular vacc...

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

RATIONALE: Vaccines made from a person's tumor cells, such as gp96 heat shock protein-peptide complex, may help the body build an effective immune response to kill tumor cells. PURP...

Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma

Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct...

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than...

A Comparison Between Conventional Surgery and Piezosurgery

Evaluation of the effect of conventional and piezo-surgery on the secretion of Heat Shock Protein (HSP70) and on the vial bone cells at the peripheral bone cut sides after the removal of i...

PubMed Articles [16629 Associated PubMed Articles listed on BioPortfolio]

THE ROLE OF AUTOIMMUNE REACTIVITY INDUCED BY HEAT SHOCK PROTEIN 70 IN THE PATHOGENESIS OF ESSENTIAL HYPERTENSION.

Autoimmunity is increasingly recognized as having a central role in essential hypertension. Heat shock proteins are immunodominant molecules with high interspecies homology and autoimmune reactivity d...

Exploration of Benzothiazole-Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70).

Cancer cells rely on the chaperone, heat shock protein 70 (Hsp70), for survival and proliferation. Recently, benzothiazole-rhodacyanines have been shown to bind an allosteric site on Hsp70, interrupti...

A novel electrochemical immunosensor based on PG for early screening of depression markers-heat shock protein 70.

In this study, a novel electrochemical immunosensor for early screening of depression markers-heat shock protein 70 (HSP70) was successfully developed based on the porous graphene (PG) with huge speci...

Hsf1 and Hsp70 constitute a two-component feedback loop that regulates the yeast heat shock response.

Models for regulation of the eukaryotic heat shock response typically invoke a negative feedback loop consisting of the transcriptional activator Hsf1 and a molecular chaperone. Previously we identifi...

Effects of celastrol on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SY5Y neuroblastoma cells induced by amyloid-β peptides.

To observe the effects of celastrol on Tau hyperphosphorylation induced by amyloid-β peptides (Aβ) in SH-SY5Y neuroblastoma cells, the changes of Tau hyperphosphorylation and the expression of heat ...

Medical and Biotech [MESH] Definitions

A family of heat-shock proteins that contain a 70 amino-acid consensus sequence known as the J domain. The J domain of HSP40 heat shock proteins interacts with HSP70 HEAT-SHOCK PROTEINS. HSP40 heat-shock proteins play a role in regulating the ADENOSINE TRIPHOSPHATASES activity of HSP70 heat-shock proteins.

A group of eukaryotic high-molecular mass heat-shock proteins that represent a subfamily of HSP70 HEAT-SHOCK PROTEINS. Hsp110 proteins prevent protein aggregation and can maintain denatured proteins in folding-competent states.

A constitutively expressed subfamily of the HSP70 heat-shock proteins. They preferentially bind and release hydrophobic peptides by an ATP-dependent process and are involved in post-translational PROTEIN TRANSLOCATION.

A subfamily of small heat-shock proteins that are closely related to ALPHA B-CRYSTALLIN. Hsp20 heat-shock proteins can undergo PHOSPHORYLATION by CYCLIC GMP-DEPENDENT PROTEIN KINASES.

Stress-inducible members of the heat-shock proteins 70 family. HSP72 heat shock proteins function with other MOLECULAR CHAPERONES to mediate PROTEIN FOLDING and to stabilize pre-existent proteins against aggregation.

More From BioPortfolio on "Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...


Searches Linking to this Trial